Summit on Novel Vaccine Technologies Successfully Concludes in Hangzhou!

Hangzhou, August 6, 2024 – The "Novel Vaccine Technologies Summit," hosted by Hangzhou Cobetter Filtration Equipment Co., Ltd., successfully concluded in Hangzhou. The forum brought together leading industry experts and scholars to explore the latest advancements and future trends in novel vaccine technologies. During the event, Cobetter's application technology team also presented the company's related products and technologies for vaccine R&D and production, fostering a shared dialogue on a promising future.

Highlight Moment

New Product Launch: Topene™ RB Single-Use Multi-Layer Co-extrusion Blown Film

Cobetter's fully self-produced single-use multi-layer co-extrusion blown film utilizes internationally advanced 11-layer co-extrusion blown film technology. Manufactured in an ultra-clean (Class 100) inner film environment with stringent quality control and pre-delivery inspection, it exemplifies precision and meticulous craftsmanship. By controlling key core technologies, Cobetter provides users with a more stable and high-quality primary film option.

Strategic Signings

Changchun BCHT & Cobetter

BCHT Biotechnology is an innovative biopharmaceutical company primarily dedicated to infectious disease prevention and control. Since its establishment in 2004, it has been engaged in the R&D, production, and sales of human vaccines. Through years of development, it has built a complete operational system around core products, implementing full lifecycle quality management encompassing raw material procurement, project R&D, production management, product distribution, quality control, and quality assurance, all governed by strict management measures and internal controls.

Jiangsu Kunli Biopharmaceutical & Cobetter

Kunli Biopharmaceutical Co., Ltd. focuses on the R&D and commercialization of novel bacterial vaccines, committed to reducing and eliminating the burden of infections caused by bacteria such as Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, Neisseria, Salmonella, and Bordetella.

Agenda Overview

The conference commenced under the moderation of Ms. Xie Hongyan, Vice President of Cobetter.

Opening Address by Kevin, CEO of Hangzhou Cobetter Filtration Equipment Co., Ltd.

Kevin first extended a warm welcome to the distinguished vaccine industry experts and scholars gathered in Hangzhou from afar. He stated that Cobetter has always been committed to providing high-performance products and services for the biopharmaceutical field and expressed hope that this forum would further strengthen collaboration to jointly advance novel vaccine technologies. Quoting the poetic line, "Endless lotus leaves join the azure sky; exceptionally red lotus blossoms bathed in sunshine," which describes the summer beauty of West Lake, Kevin also used it to symbolize his vision for a bright future in the biopharmaceutical industry.

Presentation: Mr. Jiang Chunlai, Vice President, Changchun BCHT

Topic: The Vaccine R&D Journey - A Case Study of Live Attenuated Influenza Vaccine

Mr. Jiang detailed the R&D process of the live attenuated influenza vaccine, covering stages from early research to clinical trials, and highlighted the vaccine's crucial role in influenza prevention. He shared valuable insights into the challenges and opportunities encountered during vaccine development.

Presentation: Ms. Yan Jinghua, Principal Scientist & Doctoral Supervisor, Changping Laboratory

Topic: A Success Story of Reverse Vaccinology: RSV Vaccine Antigen Design

Professor Yan provided an accessible introduction to the principles of reverse vaccinology and its application in Respiratory Syncytial Virus (RSV) vaccine antigen design. Using case studies, she shared innovative design strategies that can effectively enhance vaccine immunogenicity and protective efficacy.

Presentation: Mr. Wang Yang, Vice President, Wuhan Binhui Biotech

Topic: New Breakthroughs and Innovative R&D Strategies in Oncolytic Virus Therapy

Mr. Wang presented recent research progress in oncolytic viruses as an emerging cancer treatment. He discussed the unique advantages of oncolytic virus therapy in oncology and shared advanced information on innovative R&D strategies to further improve its therapeutic efficacy.

Presentation: Mr. Zhao Zhiqiang, Chairman & General Manager, Jiangsu Kunli Biopharmaceutical

Topic: The Significance and Progress in Developing Pathogenic Escherichia coli Vaccines

Mr. Zhao outlined the hazards of pathogenic E. coli and the importance of developing related vaccines, followed by an introduction to the progress made in this field.

Presentation: Mr. Wang Daning, R&D Director, Wantai Biopharmacy

Topic: Progress in Next-Generation HPV Vaccine R&D

Mr. Wang shared the latest achievements in HPV vaccine R&D, detailing the characteristics of next-generation HPV vaccines, including higher immunogenicity, broader protection coverage, and improved safety. He also discussed their potential impact in preventing cervical cancer and other HPV-related diseases.

Presentation: Mr. Shi Li, Chairman, Yidao Biotech

Topic: Precision Development of Stable and Efficient VLP Vaccines

Mr. Shi discussed the advantages of Virus-Like Particle (VLP) vaccines and their application in vaccine development. He shared insights on how to develop stable and efficient VLP vaccines through precise design and process optimization to enhance immunogenicity and production efficiency.

Cobetter Technology Team Presentations

Presentation: Mr. Yang Meng, Life Science Application & Technology Director, Cobetter

Topic: Application of Membrane Filtration Technology in Vaccine Processes

Mr. Yang detailed the critical role of membrane filtration technology in vaccine manufacturing, including its applications in key steps such as cell culture, purification, and final product preparation. He also shared Cobetter's latest advancements in membrane filtration and how technological innovation can further improve vaccine production quality and efficiency.

Presentation: Mr. Li Cheng, Single-Use Product Technology Manager, Cobetter Life Science

Topic: Simplifying Contamination Control in Vaccine Manufacturing with Single-Use Technologies

Mr. Li emphasized the importance of single-use technologies in vaccine production, particularly their role in simplifying processes and enhancing efficiency. He introduced how Cobetter's single-use products help vaccine manufacturers effectively control contamination risks, ensuring product safety and consistency.

Presentation: Dr. Hao Pengchao, Strategic Technology Director, Life Science, Cobetter

Topic: Guidelines for Pre- and Post-Market Changes in Process Components for Drug Manufacturing & Special Requirements for the Vaccine Industry

Dr. Hao shared practical cases regarding change management for process components used in drug production before and after market approval. He focused on the special requirements of the vaccine industry for such changes and how to ensure compliance with regulatory standards to safeguard vaccine safety and efficacy.

Closing Remarks

Gathering from afar, we convened for a shared, promising future. With the successful conclusion of the "Novel Vaccine Technologies Summit," we look forward to continuing, alongside industry colleagues, to explore the boundless possibilities of novel vaccine technologies and contribute to global health. Cobetter will remain true to its original intention, continually exploring new technologies across the filtration, separation, and purification industry chain to provide superior integrated solutions for the vaccine industry.